Cancer Therapy Due to Apoptosis: Galectin-9.
Cancer Therapy Due to Apoptosis: Galectin-9.
复制标题
DOI：
10.3390/ijms18010074
复制
发表时间：
2017-01-01
影响因子：
5.6
通讯作者：
Masaki T
中科院分区：
文献类型：
--
作者：
Fujita K;Iwama H;Oura K;Tadokoro T;Samukawa E;Sakamoto T;Nomura T;Tani J;Yoneyama H;Morishita A;Himoto T;Hirashima M;Masaki T
细胞凋亡的失调是癌症生物学中的主要标志，其可能使肿瘤具有更高的恶性潜能和化学抗性。凝集素是一种非酶或抗体的碳水化合物结合蛋白，其抗癌活性已被研究了世纪。最近，半乳糖凝集素-9，它有两个不同的碳水化合物识别结构域连接的接头肽，被注意到诱导胸腺细胞和免疫细胞的凋亡。这些细胞的凋亡有助于获得性免疫的发展和调节。此外，人重组半乳糖凝集素-9，hG 9 NC（null），其缺乏接头肽的整个区域，被设计为抵抗蛋白水解。hG 9 NC（null）已经证明了抗癌活性，包括在血液学、皮肤学和胃肠道恶性肿瘤中诱导细胞凋亡。本文综述了半乳糖凝集素-9的分子特性、研究历史和诱导细胞凋亡的潜力。
Dysregulation of apoptosis is a major hallmark in cancer biology that might equip tumors with a higher malignant potential and chemoresistance. The anti-cancer activities of lectin, defined as a carbohydrate-binding protein that is not an enzyme or antibody, have been investigated for over a century. Recently, galectin-9, which has two distinct carbohydrate recognition domains connected by a linker peptide, was noted to induce apoptosis in thymocytes and immune cells. The apoptosis of these cells contributes to the development and regulation of acquired immunity. Furthermore, human recombinant galectin-9, hG9NC (null), which lacks an entire region of the linker peptide, was designed to resist proteolysis. The hG9NC (null) has demonstrated anti-cancer activities, including inducing apoptosis in hematological, dermatological and gastrointestinal malignancies. In this review, the molecular characteristics, history and apoptosis-inducing potential of galectin-9 are described.